Results 281 to 290 of about 41,794 (337)

Pharmacoeconomic Considerations in Antiarrhythmic Therapy

PharmacoEconomics, 1992
Recently, the Cardiac Arrhythmia Suppression Trial (CAST) has focused attention on the morbidity and mortality that may be associated with pharmacological antiarrhythmic therapies. While the severity and frequency of adverse effects vary among the available agents, it is uncertain whether initial therapy with one agent is preferable to that with ...
P J, Podrid, R J, Arnold, D J, Kaniecki
openaire   +2 more sources

Antiarrhythmic Drug Therapy During Pregnancy

Annals of Internal Medicine, 1983
Pregnancy increases the work demands on the heart by increasing blood volume and thereby cardiac output. Therefore, in pregnant patients with organic heart disease, arrhythmias may have significant hemodynamic consequences to the mother with harm to the fetus.
H H, Rotmensch, U, Elkayam, W, Frishman
openaire   +2 more sources

Therapy with Investigational Antiarrhythmic Drugs

Medical Clinics of North America, 1984
The investigational antiarrhythmic agents available for use in this country are predominantly class I drugs with local anesthetic membrane effects. These drugs are often used successfully to control arrhythmias refractory to treatment with the standard antiarrhythmic drugs.
R H, Mead, D C, Harrison
openaire   +2 more sources

Antiarrhythmic Drug Therapy for Atrial Fibrillation

Heart Failure Clinics, 2014
Atrial fibrillation (AF) is the most frequently encountered arrhythmia. Prevalence increases with advancing age and so as its associated comorbidities, like heart failure. Choice of pharmacologic therapy depends on whether the goal of treatment is maintaining sinus rhythm or tolerating AF with adequate control of ventricular rates.
Muhammad Rizwan, Sardar, Wajeeha, Saeed, Peter R, Kowey   +2 more
openaire   +3 more sources

Antiarrhythmic therapy in atrial fibrillation

Pharmacology & Therapeutics, 2010
Currently available antiarrhythmic drugs for the management of AF are not sufficiently effective and are burdened with cardiac and extracardiac side effects that may offset their therapeutic benefits. Better knowledge about the mechanisms underlying generation and maintenance of AF may lead to the discovery of new targets for pharmacological ...
openaire   +2 more sources

Future Trends in Antiarrhythmic Therapy

Journal of Cardiovascular Pharmacology, 1991
It is difficult to define what the trends will be in antiarrhythmic therapy in the coming years, particularly at a time when rhythmology has been somewhat destabilized by the unexpected results of large therapeutic trials on sudden death prevention. Schematically, drugs that do have established antiarrhythmic properties do not provide any benefit, and ...
openaire   +2 more sources

Advances in Antiarrhythmic Drug Therapy

1992
Publisher Summary Recently, electrophysiologic studies have suggested that the arrhythmias leading to sudden cardiac death may have a different mechanism and pathophysiology from those producing frequent premature ventricular contractions. This has led to the speculation that agents that affect the duration of the action potential and His-Purkinje ...
D C, Harrison, M B, Bottorff
openaire   +2 more sources

New Approaches to Antiarrhythmic Therapy

New England Journal of Medicine, 1981
Concepts of antiarrhythmic therapy have undergone major changes in the past decade for a variety of reasons. First of all, electrophysiologic studies — ushered in by the observation1 that His-bundle activation could be recorded simply, safely, and reliably in human beings — have progressed from academic, research-oriented tools providing important data
openaire   +2 more sources

Antiarrhythmic Therapy for Ventricular Arrhythmias

Journal of Cardiovascular Pharmacology, 1991
Treatment of ventricular arrhythmias has received great attention during the past 20 years. However, results of recent trials with class I antiarrhythmic drugs in patients after myocardial infarction have raised many questions about the risk-benefit ratio of antiarrhythmic therapy, at least in asymptomatic subjects.
openaire   +2 more sources

Adjunctive Antiarrhythmic Drug Therapy

2002
This chapter briefly reviews the aims and outcome of antiarrhythmic drug therapy in ICD recipients. It should be stated at the outset that very few controlled trials of antiarrhytlunic drug therapy in ICD recipients have been reported. Early ICD trials were designed to allow comparisons between patients randomized to ICD therapy or “conventional ...
Philip D. Henry, Antonio Pacifico
openaire   +1 more source